Historical mrna News Stories

Moderna Secures CEPI Grant; Shares Under Pressure!

Moderna won a $54.3M CEPI award to advance its mRNA‑1018 bird flu vaccine into a pivotal trial, while new FDA vaccine standards and a string of analyst downgrades have pushed MRNA shares toward 52‑week lows. This article summarizes the funding, trial plans, regulatory impact, and what investors should monitor next.

Moderna Falls After FDA Memo on Pediatric Risk

A leaked internal FDA memorandum proposing tougher vaccine approval standards and flagging potential pediatric myocarditis deaths rattled investors this week. Moderna shares fell sharply, dragging other vaccine names lower and raising questions about near-term regulatory hurdles for mRNA-based products.

Moderna Shorted Heavily; $140M Backs Norwood Build

Recent reporting shows Moderna has become one of the most heavily shorted large-cap names while simultaneously committing $140 million to complete a domestic mRNA manufacturing site in Norwood. This article explains the short-interest dynamics, the strategic manufacturing investment, and how these developments affect MRNA stock.

Moderna Boosts Liquidity; Q3 Revenue Pressures Q4!

Moderna secured a $1.5B non-dilutive credit facility, committed $140M to complete U.S. mRNA manufacturing, and reported a Q3 revenue decline with narrowed full-year guidance. These concrete actions strengthen liquidity and operational control but leave near-term revenue and profitability challenges that investors should weigh against upcoming clinical and commercial catalysts.

Moderna Hits Turbulence: Q3 Results, CMV Cut, Vote

Moderna's recent week brought a mixed signal: a Q3 revenue beat but narrower guidance, termination of the CMV program, and a shareholder vote on an option exchange that could reduce dilution. Analysts remain cautious while institutional moves show both trimming and new interest.

Moderna Gains FDA Nod; US Cancels $766M Flu Deal!!

Moderna won FDA approval for its next‑generation COVID vaccine mNEXSPIKE while the U.S. government simultaneously cancelled roughly $766M in bird‑flu vaccine contracts — a one‑two punch that produced mixed signals for MRNA stock, combining immediate commercial upside with a loss of government funding and political headwinds.